BioCryst Pharmaceuticals, Inc. (BCRX) AI Stock Analysis
BCRX AI stock analysis summary
AI ResearchBioCryst Pharmaceuticals, Inc. (BCRX) is a commercial-stage biotechnology company developing novel oral small-molecule medicines. In FY2025, the company achieved profitability with net income of $263.9M on revenue of $874.8M. However, trailing twelve month net results remain negative with an eps_ttm of -$1.40 and negative shareholders' equity of -$454.3M as of June 30, 2026.
- Market cap
- $1.99B
- Revenue (TTM)
- $940.6M
- P/E
- — fwd 14.5x
- 1Y return
- 15.9% S&P 500 16.8%
- Avg. target
- $20.73 166.1% vs last close
Bull case
- BioCryst delivered FY2025 revenue of $874.8M with strong free cash flow generation of $327.4M.
- Trailing twelve month operating margin reached 45.1%, significantly above the US-listed Healthcare peer median of 14.0%.
- Analyst consensus targets a mean price of $20.73, indicating 166.1% upside potential from the last close of $7.79.
Bear case
- The balance sheet carries negative shareholders' equity of -$454.3M and net debt of $57.3M as of June 30, 2026.
- Trailing twelve month net results remain negative, reflected in an eps_ttm of -$1.40 and a net profit margin of -40.9%.
- Analyst estimates project full-year FY2026 revenue of $710.1M, which is lower than the $874.8M generated in FY2025.
What BioCryst Pharmaceuticals does
BioCryst Pharmaceuticals, Inc. is a Durham, North Carolina-based biotechnology company focused on discovering oral small-molecule therapies. Its commercial portfolio includes peramivir injection, marketed as RAPIVAB, RAPIACTA, and PERAMIFLU for acute uncomplicated influenza, and ORLADEYO for hereditary angioedema. Its pipeline includes BCX9930 in Phase II trials for complement-mediated diseases, BCX9250 in Phase I trials for fibrodysplasia ossificans progressiva, and Galidesivir in Phase I trials for viral infections like Marburg, Yellow Fever, Ebola, and Zika. The company maintains collaborations with entities such as Torii Pharmaceutical, Seqirus UK, Shionogi, Green Cross, Mundipharma, NIAID, and BARDA.
Growth and profitability
Revenue expanded from $157.2M in FY2021 to $874.8M in FY2025, reflecting a 5-year revenue CAGR of 117.9%. Gross margin remained high throughout this period, reaching 97.8% in FY2025. Operating margin turned positive in FY2025 at 39.0%, up from -0.6% in FY2024 and -113.1% in FY2021. Net income reached $263.9M with diluted EPS of $1.32 in FY2025. In the trailing twelve months ended June 30, 2026, revenue stood at $940.6M with an operating margin of 45.1%, though profit margin was -40.9%. For the quarter ended June 30, 2026, quarterly revenue growth was 33.6% year-over-year.
Balance sheet and cash flow
As of June 30, 2026, BioCryst held $352.6M in cash and short-term investments against total debt of $409.9M, resulting in net debt of $57.3M. Total assets stood at $557.9M, and the current ratio was 2.32. Shareholders' equity was -$454.3M. In FY2025, operating cash flow reached $329.9M and free cash flow was $327.4M, supported by low capital expenditures of $2.5M. The share count increased 45.8% over the past 5 years.
Valuation and performance
BioCryst trades at a forward P/E of 14.5x, below the 17.3x median of its US-listed Healthcare peers. Its enterprise value to EBITDA sits at 7.2x compared to the peer median of 12.0x, and its price-to-sales multiple is 2.1x versus the peer median of 4.1x. Price-to-book stands at 56.6x. Over the past year, BCRX returned 15.9%, slightly below the S&P 500 (SPY) return of 16.8%. Over a 5-year span, the stock fell 48.5%, while the S&P 500 gained 83.0%.
What analysts expect
Wall Street analysts hold 7 Strong Buy, 2 Buy, and 2 Hold ratings on BCRX, with no Sell ratings. The mean price target is $20.73, representing an upside of 166.1% over the last close of $7.79 on October 16, 2026. For the fiscal year ending December 31, 2026, analysts estimate EPS of $0.74 on revenue of $710.1M. BioCryst beat EPS estimates in each of the last 4 quarters, and its next earnings date is November 2, 2026.
Key risks and what to watch
- Negative shareholders' equity of -$454.3M highlights lingering balance sheet deficits from accumulated losses.
- Short interest stands at 10.8% of float, reflecting substantial market skepticism.
- The stock has lagged broader benchmarks over the long term, falling 48.5% over 5 years while the S&P 500 rose 83.0%.
AI-generated research summary. Written with AI from Quotelinks data as of October 16, 2026 and checked so every figure matches that data. For information only, not investment advice. Disclaimer
About this BCRX AI stock analysis
This page is an AI-written research summary of BioCryst Pharmaceuticals, Inc. (BCRX). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.
Related: BCRX income statement, BCRX balance sheet, BCRX key metrics, BCRX analyst forecast, BCRX chart. See the BCRX stock overview for the latest quote and news.
BCRX AI stock analysis FAQ
What products does BioCryst Pharmaceuticals market?
BioCryst markets peramivir injection under names such as RAPIVAB, RAPIACTA, and PERAMIFLU for influenza, as well as ORLADEYO for hereditary angioedema.
Is BioCryst Pharmaceuticals profitable?
The company reported positive net income of $263.9M and EPS of $1.32 in FY2025. However, on a trailing twelve month basis through June 30, 2026, eps_ttm was -$1.40.
What is the analyst outlook for BCRX stock?
Of 11 analyst ratings, 9 are Buy or Strong Buy and 2 are Hold. The mean price target is $20.73, which is 166.1% above the stock's closing price of $7.79 on October 16, 2026.
Does BioCryst pay a dividend?
No, BioCryst Pharmaceuticals does not currently pay a dividend.